Mead Johnson (MJN) Rebounds; FDA, CDC Affirm of Enfamil Safety
Tweet
Share
E-mailGet Alerts MJN Hot Sheet
Join SI Premium – FREE
Mead Johnson Nutrition (NYSE: MJN) is looking healthy Tuesday, following reports that the U.S. Food and Drug Administration and the Centers for Disease Control (CDC) that health inspectors have completed their testing on all formula samples collected from the company -- including Enfamil PREMIUM Newborn -- confirming that the Mead Johnson products were safe, and no presence of Cronobacter was detected.
Shares are up 5.5 percent early Tuesday.
Shares are up 5.5 percent early Tuesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sunshine Biopharma reports tumor suppression results with K1.1 mRNA program
- Caliway gets FDA clearance for CBL-514 combo trial, starts Phase 3
- INmune Bio files for EMA orphan drug status for its RDEB cell therapy
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
